Therapy with a GLP-1 RA or sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor) that has proven CV benefit is recommended for initial therapy, with or without metformin based on glycemic needs, in patients with indicators of high-risk or established CV disease
[DOI] [PMC free article] [PubMed] [Google Scholar] 13.Scirica B.M., Lincoff A.M., Lingvay I., Bogdanski P., Buscemi S., Colhoun H., Craciun A.E., Ezhov M., Hardt-Lindberg S., Kleist Jeppesen O., et al
Similar studies of Lillys drugs have shown there may be risks to the fetus from exposure during pregnancy, the company said
Clinical studies suggest berberine may help lower fasting blood glucose and reduce insulin resistance in some individuals